Drug Profile
Pictrelisib - Genentech
Alternative Names: GDC-0941; Pictilisib; RG-7321Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator PIramed; The Institute of Cancer Research
- Developer Brighton & Sussex University Hospitals NHS Trust; Genentech; Roche
- Class Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 06 Dec 2022 Efficacy data from a phase II OPPORTUNE trial in Breast cancer (Combination therapy, First-line therapy) presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS-2022)
- 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
- 01 Apr 2016 Genentech completes a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) in USA, Australia, Spain, Russia, Israel, Hungary, Argentina, Netherlands, United Kingdom, Ukraine, Italy, Germany, France, Chile, Canada, Brazil (PO) (NCT01493843)